Pediatric Radiology, Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.
Pediatr Radiol. 2012 Sep;42(9):1089-98. doi: 10.1007/s00247-012-2423-1. Epub 2012 Jul 1.
Progeria is a rare segmental premature aging disease with significant skeletal abnormalities. Defining the full scope of radiologic abnormalities requires examination of a large proportion of the world's progeria population (estimated at 1 in 4 million). There has been no comprehensive prospective study describing the skeletal abnormalities associated with progeria.
To define characteristic radiographic features of this syndrome.
Thirty-nine children with classic progeria, ages 2-17 years, from 29 countries were studied at a single site. Comprehensive radiographic imaging studies were performed.
Sample included 23 girls and 16 boys-the largest number of patients with progeria evaluated prospectively to date. Eight new and two little known progeria-associated radiologic findings were identified (frequencies of 3-36%). Additionally, 23 commonly reported findings were evaluated. Of these, 2 were not encountered and 21 were present and ranked according to their frequency. Nine abnormalities were associated with increasing patient age (P = 0.02-0.0001).
This study considerably expands the radiographic morphological spectrum of progeria. A better understanding of the radiologic abnormalities associated with progeria and improved understanding of the biology of progerin (the molecule responsible for this disease), will improve our ability to treat the spectrum of bony abnormalities.
进行性骨化性纤维发育不良是一种罕见的节段性过早衰老疾病,伴有明显的骨骼异常。要确定放射学异常的全貌,需要检查世界上相当大比例的进行性骨化性纤维发育不良患者(估计为每 400 万人中有 1 人)。以前没有全面的前瞻性研究描述与进行性骨化性纤维发育不良相关的骨骼异常。
定义该综合征的特征性放射学特征。
在一个地点对来自 29 个国家的 39 名年龄在 2-17 岁的经典进行性骨化性纤维发育不良儿童进行了综合放射影像学研究。
该样本包括 23 名女孩和 16 名男孩,这是迄今为止对进行性骨化性纤维发育不良患者进行的最大规模的前瞻性评估。确定了 8 种新的和 2 种鲜为人知的与进行性骨化性纤维发育不良相关的放射学发现(频率为 3-36%)。此外,还评估了 23 种常见报道的发现。其中,有 2 种未发现,21 种存在并根据其频率进行了排名。有 9 种异常与患者年龄的增加有关(P=0.02-0.0001)。
本研究大大扩展了进行性骨化性纤维发育不良的放射形态谱。更好地了解与进行性骨化性纤维发育不良相关的放射学异常,并更好地了解导致这种疾病的核纤层蛋白(负责这种疾病的分子)的生物学特性,将提高我们治疗各种骨异常的能力。